Understand the source comparison
Peptide Protocols for Sarcopenia: Research Evidence Comparison
CJC-1295 + Ipamorelin GHRH analog + ghrelin mimetic. Amplifies GH pulse amplitude and duration 200–300mcg each per injection 3–5 times weekly, pre-training or bedtime Moderate (Phase 2 trials, peer-reviewed observational data) Strongest evidence for lean mass
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- CJC-1295 + Ipamorelin
- GHRH analog + ghrelin mimetic. Amplifies GH pulse amplitude and duration
- 200–300mcg each per injection
- 3–5 times weekly, pre-training or bedtime
- Moderate (Phase 2 trials, peer-reviewed observational data)
- Strongest evidence for lean mass gains in older adults when paired with resistance training. Pulsatile GH release better mimics natural physiology
- MK-677 (Ibutamoren)
- Oral ghrelin receptor agonist. Sustained 24-hour GH elevation
- 12.5–25mg daily
- Once daily, evening preferred
- High (multiple Phase 2 trials, long-term safety data)
- Convenient oral dosing and sustained IGF-1 elevation, but requires glucose monitoring and appetite management. Best for individuals who won't comply with injection protocols
- Hexarelin
- Ghrelin analog with cardioprotective effects
- 100–200mcg per injection
- 1–2 times daily, fasted state
- Moderate (Phase 1/2 data, limited long-term studies)
- Potent GH release but potential for receptor desensitization with chronic use. Typically cycled 8–12 weeks on, 4 weeks off to maintain efficacy
- GHRP-2
- Growth hormone-releasing peptide. Stimulates pituitary GH secretion
- 100–300mcg per injection
- 2–3 times daily, fasted state
- Moderate (older peptide class, extensive anecdotal use, limited recent trials)
- Less selective than newer GHSs, with greater cortisol and prolactin stimulation. Effective but less refined pharmacology compared to Ipamorelin